Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Crohn's disease
Biotech
TScan’s strategy unaffected by Amgen scrapping $500M+ collab
“There are no planned changes to our wholly owned programs as a result of the Amgen collaboration being terminated,” TScan told Fierce.
Darren Incorvaia
Aug 19, 2026 5:31pm
Caldera hits Nasdaq via Synlogic reverse merger
Jul 29, 2026 8:56am
cAMPfield harvests $180M series A to advance oral IBD asset
Jun 18, 2026 10:34am
Merck hands over $20M in IBD target deal with Quotient
Mar 24, 2026 6:00am
Teva's $400M Blackstone deal to fund Sanofi-partnered IBD drug
Mar 4, 2026 3:07am
Sanofi points to long-term efficacy of Teva-partnered IBD drug
Feb 17, 2026 8:05am
